Funding for this research was provided by:
National Institutes of Health (F30HL149151, R33CA225498, 1R01CA231112, RF1DA048811, U54CA209992, F30CA250249, T32GM007205)
Received: 9 January 2020
Accepted: 2 September 2020
First Online: 28 September 2020
: The authors declare no competing interests. For full disclosure, S.C. is a co-founder, funding recipient and scientific advisor of EvolveImmune Therapeutics; the company has no relation to this study.